609 related articles for article (PubMed ID: 35397851)
21. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
22. Maternal and perinatal outcomes of SARS-CoV-2 infection in unvaccinated pregnancies during Delta and Omicron waves.
Birol Ilter P; Prasad S; Mutlu MA; Tekin AB; O'Brien P; von Dadelszen P; Magee LA; Tekin S; Tug N; Kalafat E; Khalil A
Ultrasound Obstet Gynecol; 2022 Jul; 60(1):96-102. PubMed ID: 35441407
[TBL] [Abstract][Full Text] [Related]
23. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
24. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
Florentino PTV; Millington T; Cerqueira-Silva T; Robertson C; de Araújo Oliveira V; Júnior JBS; Alves FJO; Penna GO; Vital Katikireddi S; Boaventura VS; Werneck GL; Pearce N; McCowan C; Sullivan C; Agrawal U; Grange Z; Ritchie LD; Simpson CR; Sheikh A; Barreto ML; Rudan I; Barral-Netto M; Paixão ES
Lancet Infect Dis; 2022 Nov; 22(11):1577-1586. PubMed ID: 35952702
[TBL] [Abstract][Full Text] [Related]
25. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.
Wolter N; Jassat W; Walaza S; Welch R; Moultrie H; Groome M; Amoako DG; Everatt J; Bhiman JN; Scheepers C; Tebeila N; Chiwandire N; du Plessis M; Govender N; Ismail A; Glass A; Mlisana K; Stevens W; Treurnicht FK; Makatini Z; Hsiao NY; Parboosing R; Wadula J; Hussey H; Davies MA; Boulle A; von Gottberg A; Cohen C
Lancet; 2022 Jan; 399(10323):437-446. PubMed ID: 35065011
[TBL] [Abstract][Full Text] [Related]
26. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336
[TBL] [Abstract][Full Text] [Related]
27. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
[TBL] [Abstract][Full Text] [Related]
28. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.
Lauring AS; Tenforde MW; Chappell JD; Gaglani M; Ginde AA; McNeal T; Ghamande S; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Halasa N; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Adams K; Schrag SJ; Olson SM; Kobayashi M; Verani JR; Patel MM; Self WH;
BMJ; 2022 Mar; 376():e069761. PubMed ID: 35264324
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
Krutikov M; Stirrup O; Nacer-Laidi H; Azmi B; Fuller C; Tut G; Palmer T; Shrotri M; Irwin-Singer A; Baynton V; Hayward A; Moss P; Copas A; Shallcross L;
Lancet Healthy Longev; 2022 May; 3(5):e347-e355. PubMed ID: 35531432
[TBL] [Abstract][Full Text] [Related]
30. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
31. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
32. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
34. Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves.
Doll MK; Waghmare A; Heit A; Levenson Shakoor B; Kimball LE; Ozbek N; Blazevic RL; Mose L; Boonyaratanakornkit J; Stevens-Ayers TL; Cornell K; Sheppard BD; Hampson E; Sharmin F; Goodwin B; Dan JM; Archie T; O'Connor T; Heckerman D; Schmitz F; Boeckh M; Crotty S
JAMA Netw Open; 2023 Feb; 6(2):e231181. PubMed ID: 36853602
[TBL] [Abstract][Full Text] [Related]
35. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
[TBL] [Abstract][Full Text] [Related]
36. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
[TBL] [Abstract][Full Text] [Related]
37. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study.
Gottlieb M; Wang RC; Yu H; Spatz ES; Montoy JCC; Rodriguez RM; Chang AM; Elmore JG; Hannikainen PA; Hill M; Huebinger RM; Idris AH; Lin Z; Koo K; McDonald S; O'Laughlin KN; Plumb ID; Santangelo M; Saydah S; Willis M; Wisk LE; Venkatesh A; Stephens KA; Weinstein RA;
Clin Infect Dis; 2023 Jun; 76(11):1930-1941. PubMed ID: 36705268
[TBL] [Abstract][Full Text] [Related]
38. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China.
Yang Y; Guo L; Yuan J; Xu Z; Gu Y; Zhang J; Guan Y; Liang J; Lu H; Liu Y
Lancet Microbe; 2023 Aug; 4(8):e632-e641. PubMed ID: 37459867
[TBL] [Abstract][Full Text] [Related]
39. Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.
Eyre DW; Futschik M; Tunkel S; Wei J; Cole-Hamilton J; Saquib R; Germanacos N; Dodgson AR; Klapper PE; Sudhanva M; Kenny C; Marks P; Blandford E; Hopkins S; Peto TEA; Fowler T
Lancet Infect Dis; 2023 Aug; 23(8):922-932. PubMed ID: 37001541
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Dayan GH; Rouphael N; Walsh SR; Chen A; Grunenberg N; Allen M; Antony J; Asante KP; Bhate AS; Beresnev T; Bonaparte MI; Celle M; Ceregido MA; Corey L; Dobrianskyi D; Fu B; Grillet MH; Keshtkar-Jahromi M; Juraska M; Kee JJ; Kibuuka H; Koutsoukos M; Masotti R; Michael NL; Neuzil KM; Reynales H; Robb ML; Villagómez Martínez SM; Sawe F; Schuerman L; Tong T; Treanor J; Wartel TA; Diazgranados CA; Chicz RM; Gurunathan S; Savarino S; Sridhar S;
Lancet Respir Med; 2023 Nov; 11(11):975-990. PubMed ID: 37716365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
